Sandoz entered into two separate settlement agreements this week, agreeing to pay a total of $478.5 million to resolve antitrust litigation over generic‑drug pricing in the United States.\n\nUnder the first agreement, the Swiss generic‑drug maker committed to pay $400 million over seven years starting in 2027 to settle all remaining claims brought by a consortium of 43 U.S. states and territories, plus an additional $50 million to states that settled earlier.\n\nThe second settlement covers class‑action litigation from indirect reseller plaintiffs, with Sandoz agreeing to pay $28.5 million to resolve all remaining claims related to the pricing dispute.\n\nTogether, the two agreements eliminate remaining U.S. state and reseller claims, concluding the company’s antitrust litigation and preventing future liability in these matters.\n\nThe settlement reflects increasing scrutiny of pharmaceutical pricing practices by regulators and the public, as generic manufacturers face pressure to keep prices competitive. Sandoz’s agreement signals a broader trend of large drug companies settling complex litigation to avoid prolonged court battles.\n\nThe payment schedule, with the bulk payable in the future, allows Sandoz to manage cash flow while fulfilling its obligations. Legal experts note that the agreements also include compliance measures to prevent future pricing irregularities.